[{"edinetCode":"E00816","endDate":"2017\/12\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":7532.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":382539000.0,"sharesOwendPercent":0.6636,"outstandingShares":null,"numberOfSubsidiary":null,"bps":1133.91,"equityRatio":0.88,"cashAndCashEquivalents":15759000000.0,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":34035000000.0,"eps":48.16,"dilutedEps":48.1,"dividendPerShare":null,"per":45.2,"roe":0.043,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"asr","submitDate":"2018\/3\/16","stockCode":4151,"accountingYear":"第95期（自　2017年１月１日　至　2017年12月31日）","accountingYearStart":"2017\/1\/1","accountingYearEnd":"2017\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00816","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":26745,"settlementDate":"2022\/12\/31","submitterName":"協和キリン株式会社","submitterNameEnglish":"Kyowa Kirin Co.,Ltd.","submitterNameKana":"キョウワキリンカブシキガイシャ","location":"千代田区大手町一丁目９番２号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00816","endDate":"2018\/12\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":7242.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":391654000.0,"sharesOwendPercent":0.7154,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":20.9,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"asr","submitDate":"2019\/3\/14","stockCode":4151,"accountingYear":"第96期（自　2018年１月１日　至　2018年12月31日）","accountingYearStart":"2018\/1\/1","accountingYearEnd":"2018\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00816","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":26745,"settlementDate":"2022\/12\/31","submitterName":"協和キリン株式会社","submitterNameEnglish":"Kyowa Kirin Co.,Ltd.","submitterNameKana":"キョウワキリンカブシキガイシャ","location":"千代田区大手町一丁目９番２号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00816","endDate":"2019\/3\/31","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2019\/5\/8","stockCode":4151,"accountingYear":null,"accountingYearStart":"2019\/1\/1","accountingYearEnd":"2019\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00816","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":26745,"settlementDate":"2022\/12\/31","submitterName":"協和キリン株式会社","submitterNameEnglish":"Kyowa Kirin Co.,Ltd.","submitterNameKana":"キョウワキリンカブシキガイシャ","location":"千代田区大手町一丁目９番２号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00816","endDate":"2019\/6\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":385799000.0,"sharesOwendPercent":0.7185,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q2r","submitDate":"2019\/8\/1","stockCode":4151,"accountingYear":null,"accountingYearStart":"2019\/1\/1","accountingYearEnd":"2019\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00816","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":26745,"settlementDate":"2022\/12\/31","submitterName":"協和キリン株式会社","submitterNameEnglish":"Kyowa Kirin Co.,Ltd.","submitterNameKana":"キョウワキリンカブシキガイシャ","location":"千代田区大手町一丁目９番２号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00816","endDate":"2019\/9\/30","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2019\/10\/29","stockCode":4151,"accountingYear":null,"accountingYearStart":"2019\/1\/1","accountingYearEnd":"2019\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00816","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":26745,"settlementDate":"2022\/12\/31","submitterName":"協和キリン株式会社","submitterNameEnglish":"Kyowa Kirin Co.,Ltd.","submitterNameKana":"キョウワキリンカブシキガイシャ","location":"千代田区大手町一丁目９番２号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00816","endDate":"2019\/12\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":5267.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":385041000.0,"sharesOwendPercent":0.7171,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":784453000000.0,"currentAssets":448610000000.0,"fixedAsset":null,"tangibleFixedAssets":74216000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":106204000000.0,"currentLiabilities":87530000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":26745000000.0,"capitalSurplus":463893000000.0,"accumulatedEarnings":201253000000.0,"treasuryStock":-3792000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":79620000000.0,"grossProfit":null,"sgaExpenses":117316000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":20.7,"roe":null,"cashFlowFromOperatingActivities":53655000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-933000000.0,"cashFlowFromFinancialActivities":-47371000000.0,"changesInCashAndCashEquivalents":4896000000.0,"列1":"asr","submitDate":"2020\/3\/12","stockCode":4151,"accountingYear":"第97期（自　2019年１月１日　至　2019年12月31日）","accountingYearStart":"2019\/1\/1","accountingYearEnd":"2019\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00816","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":26745,"settlementDate":"2022\/12\/31","submitterName":"協和キリン株式会社","submitterNameEnglish":"Kyowa Kirin Co.,Ltd.","submitterNameKana":"キョウワキリンカブシキガイシャ","location":"千代田区大手町一丁目９番２号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00816","endDate":"2020\/3\/31","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":773081000000.0,"currentAssets":438849000000.0,"fixedAsset":null,"tangibleFixedAssets":75894000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":100375000000.0,"currentLiabilities":81607000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":26745000000.0,"capitalSurplus":463892000000.0,"accumulatedEarnings":203209000000.0,"treasuryStock":-3678000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":19413000000.0,"grossProfit":null,"sgaExpenses":29702000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":617000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":100253000000.0,"cashFlowFromFinancialActivities":-12478000000.0,"changesInCashAndCashEquivalents":87203000000.0,"列1":"q1r","submitDate":"2020\/5\/14","stockCode":4151,"accountingYear":null,"accountingYearStart":"2020\/1\/1","accountingYearEnd":"2020\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00816","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":26745,"settlementDate":"2022\/12\/31","submitterName":"協和キリン株式会社","submitterNameEnglish":"Kyowa Kirin Co.,Ltd.","submitterNameKana":"キョウワキリンカブシキガイシャ","location":"千代田区大手町一丁目９番２号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00816","endDate":"2020\/6\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":392059000.0,"sharesOwendPercent":0.7299,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":779625000000.0,"currentAssets":433211000000.0,"fixedAsset":null,"tangibleFixedAssets":74698000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":93720000000.0,"currentLiabilities":75267000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":26745000000.0,"capitalSurplus":463925000000.0,"accumulatedEarnings":217165000000.0,"treasuryStock":-3611000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":40951000000.0,"grossProfit":null,"sgaExpenses":58234000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":20555000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":216524000000.0,"cashFlowFromFinancialActivities":-13315000000.0,"changesInCashAndCashEquivalents":222758000000.0,"列1":"q2r","submitDate":"2020\/7\/30","stockCode":4151,"accountingYear":null,"accountingYearStart":"2020\/1\/1","accountingYearEnd":"2020\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00816","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":26745,"settlementDate":"2022\/12\/31","submitterName":"協和キリン株式会社","submitterNameEnglish":"Kyowa Kirin Co.,Ltd.","submitterNameKana":"キョウワキリンカブシキガイシャ","location":"千代田区大手町一丁目９番２号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00816","endDate":"2020\/9\/30","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":781160000000.0,"currentAssets":427653000000.0,"fixedAsset":null,"tangibleFixedAssets":75778000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":95989000000.0,"currentLiabilities":73620000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":26745000000.0,"capitalSurplus":463945000000.0,"accumulatedEarnings":215038000000.0,"treasuryStock":-3578000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":58639000000.0,"grossProfit":null,"sgaExpenses":88141000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":31861000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":258676000000.0,"cashFlowFromFinancialActivities":-25914000000.0,"changesInCashAndCashEquivalents":264237000000.0,"列1":"q3r","submitDate":"2020\/10\/30","stockCode":4151,"accountingYear":null,"accountingYearStart":"2020\/1\/1","accountingYearEnd":"2020\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00816","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":26745,"settlementDate":"2022\/12\/31","submitterName":"協和キリン株式会社","submitterNameEnglish":"Kyowa Kirin Co.,Ltd.","submitterNameKana":"キョウワキリンカブシキガイシャ","location":"千代田区大手町一丁目９番２号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00816","endDate":"2020\/12\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":5423.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":389190000.0,"sharesOwendPercent":0.7245,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":801290000000.0,"currentAssets":442482000000.0,"fixedAsset":null,"tangibleFixedAssets":76012000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":102894000000.0,"currentLiabilities":80749000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":26745000000.0,"capitalSurplus":463967000000.0,"accumulatedEarnings":226639000000.0,"treasuryStock":-3545000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":80440000000.0,"grossProfit":null,"sgaExpenses":126610000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":32.1,"roe":null,"cashFlowFromOperatingActivities":39502000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":252559000000.0,"cashFlowFromFinancialActivities":-26003000000.0,"changesInCashAndCashEquivalents":266257000000.0,"列1":"asr","submitDate":"2021\/3\/9","stockCode":4151,"accountingYear":"第98期（自　2020年１月１日　至　2020年12月31日）","accountingYearStart":"2020\/1\/1","accountingYearEnd":"2020\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00816","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":26745,"settlementDate":"2022\/12\/31","submitterName":"協和キリン株式会社","submitterNameEnglish":"Kyowa Kirin Co.,Ltd.","submitterNameKana":"キョウワキリンカブシキガイシャ","location":"千代田区大手町一丁目９番２号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00816","endDate":"2021\/3\/31","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":809072000000.0,"currentAssets":442929000000.0,"fixedAsset":null,"tangibleFixedAssets":75132000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":101262000000.0,"currentLiabilities":79181000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":26745000000.0,"capitalSurplus":463995000000.0,"accumulatedEarnings":227742000000.0,"treasuryStock":-3506000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":22392000000.0,"grossProfit":null,"sgaExpenses":31651000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":14404000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-4638000000.0,"cashFlowFromFinancialActivities":-13462000000.0,"changesInCashAndCashEquivalents":-3256000000.0,"列1":"q1r","submitDate":"2021\/5\/6","stockCode":4151,"accountingYear":null,"accountingYearStart":"2021\/1\/1","accountingYearEnd":"2021\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00816","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":26745,"settlementDate":"2022\/12\/31","submitterName":"協和キリン株式会社","submitterNameEnglish":"Kyowa Kirin Co.,Ltd.","submitterNameKana":"キョウワキリンカブシキガイシャ","location":"千代田区大手町一丁目９番２号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00816","endDate":"2021\/6\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":392160000.0,"sharesOwendPercent":0.7299,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":819774000000.0,"currentAssets":452709000000.0,"fixedAsset":null,"tangibleFixedAssets":75413000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":99242000000.0,"currentLiabilities":75419000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":26745000000.0,"capitalSurplus":464100000000.0,"accumulatedEarnings":239894000000.0,"treasuryStock":-3414000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":41248000000.0,"grossProfit":null,"sgaExpenses":67246000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":23047000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-1874000000.0,"cashFlowFromFinancialActivities":-14321000000.0,"changesInCashAndCashEquivalents":5742000000.0,"列1":"q2r","submitDate":"2021\/8\/3","stockCode":4151,"accountingYear":null,"accountingYearStart":"2021\/1\/1","accountingYearEnd":"2021\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00816","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":26745,"settlementDate":"2022\/12\/31","submitterName":"協和キリン株式会社","submitterNameEnglish":"Kyowa Kirin Co.,Ltd.","submitterNameKana":"キョウワキリンカブシキガイシャ","location":"千代田区大手町一丁目９番２号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00816","endDate":"2021\/9\/30","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":856804000000.0,"currentAssets":494109000000.0,"fixedAsset":null,"tangibleFixedAssets":74940000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":143529000000.0,"currentLiabilities":87709000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":26745000000.0,"capitalSurplus":464130000000.0,"accumulatedEarnings":234514000000.0,"treasuryStock":-3391000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":64108000000.0,"grossProfit":null,"sgaExpenses":104111000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":81186000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-10777000000.0,"cashFlowFromFinancialActivities":-27555000000.0,"changesInCashAndCashEquivalents":43420000000.0,"列1":"q3r","submitDate":"2021\/11\/1","stockCode":4151,"accountingYear":null,"accountingYearStart":"2021\/1\/1","accountingYearEnd":"2021\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00816","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":26745,"settlementDate":"2022\/12\/31","submitterName":"協和キリン株式会社","submitterNameEnglish":"Kyowa Kirin Co.,Ltd.","submitterNameKana":"キョウワキリンカブシキガイシャ","location":"千代田区大手町一丁目９番２号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00816","endDate":"2021\/12\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":5752.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":398969000.0,"sharesOwendPercent":0.7425,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":921872000000.0,"currentAssets":518231000000.0,"fixedAsset":null,"tangibleFixedAssets":78652000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":184710000000.0,"currentLiabilities":109129000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":26745000000.0,"capitalSurplus":464153000000.0,"accumulatedEarnings":255528000000.0,"treasuryStock":-3359000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":87849000000.0,"grossProfit":null,"sgaExpenses":145608000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":32.2,"roe":null,"cashFlowFromOperatingActivities":86548000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-11363000000.0,"cashFlowFromFinancialActivities":-28446000000.0,"changesInCashAndCashEquivalents":48065000000.0,"列1":"asr","submitDate":"2022\/3\/8","stockCode":4151,"accountingYear":"第99期（自　2021年１月１日　至　2021年12月31日）","accountingYearStart":"2021\/1\/1","accountingYearEnd":"2021\/12\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00816","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":26745,"settlementDate":"2022\/12\/31","submitterName":"協和キリン株式会社","submitterNameEnglish":"Kyowa Kirin Co.,Ltd.","submitterNameKana":"キョウワキリンカブシキガイシャ","location":"千代田区大手町一丁目９番２号","industory":"医薬品","corporateNumber":7010000000000.0}]